Advanced Medical Isotope changes name
Medical isotope developer Advanced Medical Isotope has changed its name to...Read more on AuntMinnie.comRelated Reading: AMIC reports progress on RadioGel FDA clearance AMIC resubmits Y-90 RadioGel to FDA AMIC nets brachytherapy-related patent AMIC looks for European investors AMIC and GSG form strategic alliance
The aims of this study were to evaluate treatment responses and predictive factors for overall survival (OS) in hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) treated with iodine-125 (125I) brachytherapy.
Purpose: Radiation retinopathy remains incompletely characterized and may cause severe vision loss. Ultra–wide-field fluorescein angiography provides a pan-fundus view of vascular alterations caused by radiation treatment and may predict visual and ocular outcomes. We have developed a grading scheme to describe pan-fundus severity and to predict the progression of radiation retinopathy in patients treated for uveal melanoma with iodine-125 brachytherapy. Methods: A retrospective review of patients treated with standard iodine-125 brachytherapy for uveal melanoma at the Ophthalmic Oncology Center at the Universit...
ConclusionThe presented relationships can be developed in each individual institution and convert one dosimetric index to another for different skin definitions.
We examined 102 patients with Wang T1-T2 squamous cell carcinoma of the nasal vestibule to assess local-regional control rates and patient satisfaction after image guided brachytherapy. Furthermore, tumor volume was explored as prognostic factor for recurrence. We found that brachytherapy offers excellent local control with high patient satisfaction. Tumor volume was found to be an adequate predictive factor for patients at risk of regional recurrence.
To the Editor: We read with interest the article by Valdes et al in which machine learning methods were used to predict biochemical failure after salvage brachytherapy for prostate cancer (1). Although the article addresses a relevant clinical issue, we are concerned that there are issues with the statistical methods that undermine the conclusion of good pre dictive performance. Given the many recent papers in our field applying machine learning to clinical questions, the themes discussed in this letter may apply more broadly.
To the Editor: We would like to thank the authors for their comments on our work and for raising general points regarding statistics and machine learning that are important for public discussion (1). It was partly with the intention of generating these types of discussions that we wrote our paper, “Salvage HDR Brachytherapy: Multiple Hypothesis Testing Versus Machine Learning Analysis (2).” As such, we would like to thank the editor for giving us the opportunity to reply. We believe that our revised article, with the comments and our response, offers a better picture of the applications o f machine learning to ...
To the Editor: The work of Bauer-Nilsen et al explores time-driven activity-based cost (TDABC) and reimbursement of cervical cancer radiation therapy (1). The authors propose that high TDABC but low reimbursement could contribute to the declining use of brachytherapy. Overall, the analysis was intriguing and generated discussion among the American Society for Radiation Oncology's Code Development and Valuation Sub-Committee, which analyzes reimbursement for radiation oncology services. Although TDABC may be useful in better understanding practice cost drivers, there are limitations in the analysis that prevent genera...
To the Editor: I appreciate the comments of Orio and Goodwin and agree that a single-institution study using our research methodology is not the appropriate method for calculations to inform Centers for Medicare and Medicaid Services payment determinations (1). Instead, our priority was to compare the physician effort and relative radiation oncology physician reimbursement for the brachytherapy versus external beam radiation therapy components of the course. I agree that substantial overhead costs and different health care environments must be considered when estimating an appropriate payment policy.
DiscussionChronic inflammation can promote cell proliferation and growth. The use of immunomodulatory drugs is associated with an increased risk of developing melanoma and non-melanoma skin cancer. The two patients described in this report both had long-standing IBD treated with immunomodulatory drugs. It seems reasonable to suggest that these two factors may have promoted the development of uveal melanoma. More studies are warranted to investigate and confirm this possible association.
IMRT and 3D image-guided adapted brachytherapy (3D-IGABT) is increasingly used for definitive cervical cancer treatment. We compared patterns of failure and survival to patients treated with 2D external beam radiation and brachytherapy, with all patients receiving a pre-treatment PET and all surviving patients having 5 years minimum follow up. IMRT and 3D-IGABT was associated with higher survival and reduced late bowel and bladder toxicities.